Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Sheba Medical Center Announces Advanced CAR-T Leukemia Treatment, Saves Swiss Teenager's Life
  • USA - English


News provided by

[email protected]

May 07, 2018, 07:00 ET

Share this article

Share toX

Share this article

Share toX

CAR-T Leukemia (ALL) Treatment at Sheba Medical Center
CAR-T Leukemia (ALL) Treatment at Sheba Medical Center

RAMAT GAN, Israel (PRWEB) May 07, 2018 -- At Sheba Medical Center in Israel, a groundbreaking form of immunotherapy called CAR-T (chimeric antigen receptor) has been successful in treating acute lymphoblastic leukemia (ALL), an aggressive type of leukemia that often appears in young people.

“Without Dr. Elad Jacoby, our medical coordinator, Yana Boguslavsky, and the volunteer medical staff, Zeev Greenberg and Hasia Wolpin, we never would have survived this turning point in our life.” - Mylene's family

Post this

ALL is a cancer of the bone marrow and blood. ALL patients produce too many immature lymphocytes - white blood cells. White blood cells function as critical parts of the immune system. Therefore, patients with ALL are often unable to fight off infections effectively. Additionally, these immature white blood cells can hinder the normal production of other vital blood cells, namely platelets and red blood cells.

The symptoms of ALL are typically generalized and include fatigue, easy bruising, and frequent fevers. Doctors are usually able to diagnosis the disease through standard laboratory blood tests and bone marrow biopsy. ALL can progress rapidly and, without treatment, may cause death within just a few months after onset.

Most ALL patients receive chemotherapy as a first-line treatment. But even if chemotherapy is successful at achieving remission, patients must receive maintenance chemotherapy to kill any residual cancer. Additionally, chemotherapy is sometimes combined with radiation therapy.

Recently, novel biologic drugs for ALL have been introduced. These drugs attempt to induce the body to fight the leukemia. For example, the drug blinatumomab elicits a physiological response, causing the immune system to kill certain immature lymphocytes.

Unfortunately, even with advanced treatment, ALL cases often relapse. For these patients, immunotherapy using CAR-T may be their final lifeline. This was the case for Mylène, a Swiss teenager. She was diagnosed with ALL in January 2016. Despite high-dose chemotherapy treatment, a bone marrow transplants, and even therapy with blinatumomab, Mylène continued to suffer relapse after relapse - a total of four.

Her doctors in Switzerland referred her to experts at Sheba Hospital in Israel. At Sheba, Mylène’s treatment team recommended CAR-T immunotherapy. This form of treatment is currently only available at limited facilities. CAR-T at Sheba was Mylène’s best hope.

CAR engineered T-cells were originally invented by Prof. Dr. Zelig Eshhar at the Weizmann Institute of Science in Rehovot, Israel. Decades later, several institutions in the US established CAR-T as a therapy for ALL. In CAR-T therapy, the patient has T-cells, white blood cells that function as part of the immune system, removed and engineered with specific chimeric antigen receptors (CAR). These receptors turn the T-cells into hunter/killers to effectively fight cancer once they are introduced back into the patient’s body.

Chimeric antigen receptors are not naturally-occurring. They must be created in a specialized laboratory. The entire CAR-T immunotherapy process takes about ten days, but patients need to remain in the hospital for at least two weeks to be monitored. Although significant side effects occur in 40-60% of patients, these side effects are largely reversible. CAR-T therapy is currently limited to patients under 50 years of age.

CAR-T treatment at Sheba has produced outstanding results, particularly in young people. In fact, Sheba has achieved a 90% ALL recovery rate among children and a 70% recovery rate in the total patient population.

Dr. Elad Jacoby headed Mylène’s treatment at Sheba. Trained at the National Cancer Institute in the US, Dr. Jacoby subsequently established the CAR-T program in Israel. His skill and expertise, and that of Mylène’s entire treatment team, helped to produce a happy outcome.

Today, Mylène has overcome her persistent, relapsing leukemia. Tests have shown that the leukemia has been eliminated from her bone marrow, the areas outside her bone marrow, and her central nervous system. She is now back in Switzerland and only needs weekly consultations at University Children’s Hospital Zurich

As one of the few hospitals to house a CAR-T immunotherapy laboratory and the home of expert staff, Sheba Medical Center is proud to make this life-saving treatment affordable and accessible. Sheba is a government hospital with transparent fees and provides personalized treatment for each patient, no matter their nation of origin.

For more information regarding CAR-T and other inquiries, please contact Sheba Medical Center directly at:
[email protected] or via our official website: http://www.shebaonline.org

Yulia Yusim, [email protected], http://www.shebaonline.org, +1 3155171888, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.